Cancer Genetics and Epigenetics, 2025, Vol.13, No.2, 50-61 http://medscipublisher.com/index.php/cge 59 Conflict of Interest Disclosure The author affirms that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. Reference Akter S., Rahman M., Hasan M., Akhter H., Noor P., Shuvo R., Shin Y., Rahman M., Gazi M., Huda M.N., Nam N., Chung J., Han S., Kim B., Kang I., Ha J., Choe W., Choi T.G., and Kim S.S., 2022, Recent advances in ovarian cancer: therapeutic strategies, potential biomarkers, and technological improvements, Cells, 11(4): 650. https://doi.org/10.3390/cells11040650 An D., Banerjee S., and Lee J.M., 2021, Recent advancements of antiangiogenic combination therapies in ovarian cancer, Cancer Treatment Reviews, 98: 102224. https://doi.org/10.1016/j.ctrv.2021.102224 Bookman M.A., 2016, Optimal primary therapy of ovarian cancer, Annals of Oncology, 27: i58-i62. https://doi.org/10.1093/annonc/mdw088 Bukłaho P.A., Kiśluk J., Wasilewska N., and Nikliński J., 2023, Molecular features as promising biomarkers in ovarian cancer, Advances in Clinical and Experimental Medicine. 32(9): 1029-1040. https://doi.org/10.17219/acem/159799 Chandra A., Pius C., Nabeel M., Nair M., Vishwanatha J., Ahmad S., and Basha R., 2019, Ovarian cancer: current status and strategies for improving therapeutic outcomes, Cancer Medicine, 8(16): 7018-7031. https://doi.org/10.1002/cam4.2560 Chastek B., Bunner S., Simmons D., Blank S., ElNaggar A., and McLaurin K., 2021, Real world trends in biomarker testing in U.S. advanced ovarian cancer patients, Gynecologic Oncology, 162: S256-S257. https://doi.org/10.1016/s0090-8258(21)01137-9 Colombo P.E., Taoum C., Fabbro M., Quesada S., Rouanet P., and Ray-Coquard I., 2024, Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer, critical, Reviews in Oncology/Hematology, 202: 104469. https://doi.org/10.1016/j.critrevonc.2024.104469 Cortez A.J., Tudrej P., Kujawa K.A., and Lisowska K.M., 2017, Advances in ovarian cancer therapy, Cancer Chemotherapy and Pharmacology, 81(1): 17-38. https://doi.org/10.1007/s00280-017-3501-8 Díaz-Feijóo B., Agustí N., Sebio R., Sisó M., Carreras-Dieguez N., Domingo S., Díaz-Cambronero Ó., Torné A., Martínez-Pallí G., and Arguis M., 2022 A multimodal prehabilitation program for the reduction of post-operative complications after surgery in advanced ovarian cancer under an ERAS pathway: a randomized multicenter trial (SOPHIE), International Journal of Gynecological Cancer, 32(11): 1463-1468. https://doi.org/10.1136/ijgc-2022-003652 Dressman H.K., Berchuck A., Chan G., Zhai J., Bild A., Sayer R., Cragun J., Clarke J., Whitaker R., Li L., Gray J., Marks J., Ginsburg G., Potti A., West M., Nevins J., and Lancaster J., 2007, An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer, Journal of Clinical Oncology, 25(5): 517-525. https://doi.org/10.1200/JCO.2006.06.3743 Franco A.C.R., Batista M.G.C., Rezende E.H.M., Filho M.D.E., Schimin M.A., Filho D., Segundo R., De Araújo L., Alves N., and Pinheiro B., 2024, Epithelial ovarian cancer: the importance of early diagnosis and individualized treatment with combination chemotherapy and targeted therapy, Brazilian Journal of Implantology and Health Sciences, 6(4): 533-551. https://doi.org/10.36557/2674-8169.2024v6n4p533-551 Garbuzenko O.B., Sapiezynski J., Girda E., Rodriguez-Rodriguez L., and Minko T., 2024, Personalized versus precision nanomedicine for treatment of ovarian cancer, Small, 20(41): e2307462. https://doi.org/10.1002/smll.202307462 Garsed D.W., Pandey A., Fereday S., Kennedy C., Takahashi K., Alsop K., Hamilton P.T., Hendley J., Chiew Y., Traficante N., Provan P., Ariyaratne D., Au-Yeung G., Bateman N., Bowes L., Brand A., Christie E., Cunningham J., Friedlander M., Grout B., Harnett P., Hung J., McCauley B., Mcnally O., Piskorz A.M., Saner F.A.M., Vierkant R., Wang C., Winham S., Pharoah P., Brenton J., Conrads T., Maxwell G., Ramus S., Pearce C., Pike M., Nelson B., Goode E., Defazio A., and Bowtell D., 2022, The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer, Nature Genetics, 54(12): 1853-1864. https://doi.org/10.1038/s41588-022-01230-9 Guan L., and Lu Y., 2018, New developments in molecular targeted therapy of ovarian cancer, Discovery Medicine, 26(144): 219-229. Guy H., Hawkes C., Walder L., Malinowska I.A., and Gupta D., 2022, Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer, Future Oncology, 18(30): 3435-3447. https://doi.org/10.2217/fon-2022-0578 Hollis R., 2023, Molecular characteristics and clinical behaviour of epithelial ovarian cancers, Cancer Letters, 555: 216057. https://doi.org/10.1016/j.canlet.2023.216057 Hollis R., and Gourley C., 2016, Genetic and molecular changes in ovarian cancer, Cancer Biology and Medicine, 13: 236-247. https://doi.org/10.20892/j.issn.2095-3941.2016.0024
RkJQdWJsaXNoZXIy MjQ4ODYzNA==